ES2180279T3 - Compuesto de hierro-dextrano para utilizacion como componente en composicion terapeutica para profilaxis o tratamiento de deficiencia de hierro, procedimiento para su produccion y utilizacion del mismo para preparacion de composicion terapeutica administrable por via parenteral. - Google Patents

Compuesto de hierro-dextrano para utilizacion como componente en composicion terapeutica para profilaxis o tratamiento de deficiencia de hierro, procedimiento para su produccion y utilizacion del mismo para preparacion de composicion terapeutica administrable por via parenteral.

Info

Publication number
ES2180279T3
ES2180279T3 ES99908785T ES99908785T ES2180279T3 ES 2180279 T3 ES2180279 T3 ES 2180279T3 ES 99908785 T ES99908785 T ES 99908785T ES 99908785 T ES99908785 T ES 99908785T ES 2180279 T3 ES2180279 T3 ES 2180279T3
Authority
ES
Spain
Prior art keywords
therapeutic composition
iron
dextran
daltons
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99908785T
Other languages
English (en)
Other versions
ES2180279T5 (es
Inventor
Hans Berg Andreasen
Lars Christensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacosmos Holding AS
Original Assignee
Pharmacosmos Holding AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8093321&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2180279(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacosmos Holding AS filed Critical Pharmacosmos Holding AS
Application granted granted Critical
Publication of ES2180279T3 publication Critical patent/ES2180279T3/es
Publication of ES2180279T5 publication Critical patent/ES2180279T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Compuesto de hierro-dextrano para su utilización en la preparación de una composición terapéutica para la profilaxis o el tratamiento de la deficiencia de hierro en sujetos animales o humanos mediante una administración parenteral, que comprende dextrano hidrogenado que presenta un peso molecular medio ponderado (Mw) comprendido entre 700 y 1.400 Daltons, preferentemente aproximadamente 1.000 Daltons, un peso molecular medio numérico (Mn) de 400 a 1.400 Daltons y en el que el 90 % en peso del dextrano presenta pesos moleculares inferiores a 2.700 Daltons y el Mw del 10 % en peso de la fracción del dextrano que presenta los pesos moleculares más altos es inferior a 3.200 Daltons, habiendo sido sometido dicho dextrano hidrogenado a una purificación mediante procedimientos con membranas que presentan un valor de corte comprendido entre 340 y 800 Daltons, en asociación estable con oxihidróxido férrico.
ES99908785T 1998-03-25 1999-03-24 Compuesto hierro-dextrano para utilizacion como componente en composicion terapeutica para profilaxis o tratamiento de deficiencia de hierro, procedimiento para su produccion y su utilizacion para prepararacion composicion terapeutica que se puede administrar por via parenteral. Expired - Lifetime ES2180279T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK199800420 1998-03-25
DK199800420A DK172860B1 (da) 1998-03-25 1998-03-25 Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman

Publications (2)

Publication Number Publication Date
ES2180279T3 true ES2180279T3 (es) 2003-02-01
ES2180279T5 ES2180279T5 (es) 2009-05-05

Family

ID=8093321

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99908785T Expired - Lifetime ES2180279T5 (es) 1998-03-25 1999-03-24 Compuesto hierro-dextrano para utilizacion como componente en composicion terapeutica para profilaxis o tratamiento de deficiencia de hierro, procedimiento para su produccion y su utilizacion para prepararacion composicion terapeutica que se puede administrar por via parenteral.

Country Status (28)

Country Link
US (1) US6291440B1 (es)
EP (1) EP1066056B2 (es)
JP (1) JP4558198B2 (es)
KR (1) KR100612071B1 (es)
CN (1) CN1147322C (es)
AR (1) AR015738A1 (es)
AT (1) ATE220560T1 (es)
AU (1) AU740432B2 (es)
BR (1) BRPI9908914B8 (es)
CA (1) CA2322633C (es)
CZ (1) CZ300823B6 (es)
DE (1) DE69902154T3 (es)
DK (2) DK172860B1 (es)
EA (1) EA003427B1 (es)
ES (1) ES2180279T5 (es)
HK (1) HK1033426A1 (es)
HU (1) HU228483B1 (es)
ID (1) ID26778A (es)
NO (1) NO329591B1 (es)
NZ (1) NZ505983A (es)
PL (1) PL195582B1 (es)
PT (1) PT1066056E (es)
SI (1) SI1066056T2 (es)
SK (1) SK284499B6 (es)
TR (1) TR200002733T2 (es)
UA (1) UA70939C2 (es)
WO (1) WO1999048533A1 (es)
ZA (1) ZA200004016B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173138B1 (da) 1998-11-20 2000-02-07 Pharmacosmos Holding As Fremgangsmåde til fremstilling af en jerndextranforbindelse, jerndextranforbindelse fremstillet efter fremgangsmåden, farma
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
DE60043188D1 (de) * 1999-04-09 2009-12-03 Amag Pharmaceuticals Inc Hitzebeständige umhüllte kolloidale eisenoxide
KR20020003344A (ko) * 2001-12-17 2002-01-12 유형선 철분 보급제 경구 투여 제제 조성물
BR0308773A (pt) * 2002-04-09 2005-02-09 Pharmacosmos Holding As Compostos de dextrina de ferro para tratamento de anemia por deficiência de ferro
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
US20060116349A1 (en) * 2003-03-14 2006-06-01 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron for the treatment of restless leg syndrome
DE102004031181A1 (de) * 2004-06-28 2006-01-19 Vifor (International) Ag Phosphatadsorbens
ITMO20050056A1 (it) * 2005-03-15 2006-09-16 Biofer Spa Processo per la preparazione di complessi del ferro trivalente con zuccheri mono-, di- e polisaccaridi.
EP1757299A1 (de) 2005-08-25 2007-02-28 Vifor (International) Ag Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung
EP2626074A1 (en) 2006-01-06 2013-08-14 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron
EP1947120A1 (de) * 2007-01-19 2008-07-23 Vifor (International) Ag Eisen-Kohlenhydrat-Komplex-Verbindungen
EP1997833A1 (de) * 2007-05-29 2008-12-03 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydratderivat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
CN101585887B (zh) * 2008-05-22 2011-12-14 中国科学院过程工程研究所 应用纳滤技术对右旋糖酐铁络合物水溶液进行脱盐和浓缩的方法
EP3156075B1 (en) 2009-03-25 2020-10-14 Pharmacosmos Holding A/S An oligosaccharide and a process for preparation thereof
CN101967205B (zh) * 2010-10-12 2013-04-17 滨州学院 一种β-葡聚糖铁复合物及其制备方法
EP2537866A1 (en) 2011-06-21 2012-12-26 Serumwerk Bernburg AG Hydroxyethyl starch derivatives, method for manufacturing the same and therapeutical uses thereof
PL398814A1 (pl) 2012-04-16 2013-10-28 Uniwersytet Jagiellonski Zastosowanie pochodnych dekstranu do przeciwdzialania lub leczenia niedokrwistosci
US10172882B2 (en) 2014-06-22 2019-01-08 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
HUE045092T2 (hu) * 2014-10-27 2019-12-30 Pharmacosmos Holding As Vérszegénység kezelése vagy megelõzése vemhes nem-humán emlõsökben és utódaikban
JP7426927B2 (ja) 2017-09-11 2024-02-02 ファーマコスモス ホールディング エー／エス 治療的使用のための鉄錯体化合
CN109646454A (zh) * 2018-12-29 2019-04-19 博瑞生物医药（苏州）股份有限公司 异麦芽糖酐铁1000的制备方法
CN110183548B (zh) * 2019-06-28 2021-05-18 瑞普（天津）生物药业有限公司 一种低分子葡聚糖铁的制备方法及其应用
BR112024002150A2 (pt) 2021-08-03 2024-04-30 Pharmacosmos Holding As Compostos de complexo de ferro para uso subcutâneo na terapia de deficiência de ferro em animais de companhia

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE24642E (en) 1959-04-28 Therapeutic preparations of iron
DK117730A (es)
US2885393A (en) 1956-02-24 1959-05-05 R K Laros Company Dextran-iron complex and process for making same
US3093545A (en) 1960-08-29 1963-06-11 Armour Pharma Therapeutic iron-dextran preparations
US3234209A (en) * 1963-09-13 1966-02-08 Chemicals Inc Process for making iron hydrogenated dextran
DE1293144B (de) * 1964-11-04 1969-04-24 Hausmann Ag Labor Verfahren zur Herstellung von Komplexverbindungen des Eisens mit Sorbit, Gluconsaeure und einem Oligosaccharid
GB1183940A (en) 1966-10-22 1970-03-11 Fisons Pharmaceuticals Ltd Ferric Hydroxide Complexes
GB1200902A (en) 1967-05-13 1970-08-05 Fisons Pharmaceuticals Ltd Iron-dextran complexes
CH507993A (de) 1967-07-13 1971-05-31 Kutnowskie Zakl Farma Verfahren zur Herstellung von Eisen(III)-komplexverbindungen mit hydriertem Dextran
DK129353B (da) 1968-04-29 1974-09-30 Fisons Pharmaceuticals Ltd Analogifremgangsmåde til fremstilling af et ferrihydroxid-dextranderivatkompleks eller en opløsning deraf.
US3697502A (en) 1969-11-03 1972-10-10 Christensen Henry M Method of making iron dextran-preparations
GB1562913A (en) * 1976-06-16 1980-03-19 Fisons Ltd Fractionating fluid mixtures of dextrans
DE3422249A1 (de) * 1984-06-15 1985-12-19 Pfeifer & Langen, 5000 Köln Wasserloesliches eisendextran und verfahren zu seiner herstellung
US4827945A (en) 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US5102652A (en) * 1986-07-03 1992-04-07 Advanced Magnetics Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
IT1263831B (it) * 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
RU2093577C1 (ru) * 1993-11-04 1997-10-20 Государственный институт кровезаменителей и медицинских препаратов Способ получения декстрана
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
US5624668A (en) * 1995-09-29 1997-04-29 Luitpold Pharmaceuticals, Inc. Iron dextran formulations

Also Published As

Publication number Publication date
BRPI9908914B1 (pt) 2012-06-12
NO20004151D0 (no) 2000-08-18
NO329591B1 (no) 2010-11-15
DE69902154D1 (de) 2002-08-22
BRPI9908914A (pt) 2000-11-21
US6291440B1 (en) 2001-09-18
SI1066056T2 (sl) 2009-04-30
ATE220560T1 (de) 2002-08-15
EA003427B1 (ru) 2003-04-24
DK1066056T4 (da) 2009-04-14
CA2322633A1 (en) 1999-09-30
UA70939C2 (uk) 2004-11-15
ES2180279T5 (es) 2009-05-05
EA200000981A1 (ru) 2001-02-26
EP1066056A1 (en) 2001-01-10
SI1066056T1 (en) 2002-12-31
NO20004151L (no) 2000-08-18
PL343164A1 (en) 2001-07-30
DK172860B1 (da) 1999-08-16
SK14092000A3 (sk) 2001-04-09
CN1147322C (zh) 2004-04-28
DK1066056T3 (da) 2002-10-14
AU2827399A (en) 1999-10-18
KR100612071B1 (ko) 2006-08-11
EP1066056B2 (en) 2008-12-10
HK1033426A1 (en) 2001-08-31
CA2322633C (en) 2009-01-27
AR015738A1 (es) 2001-05-16
ID26778A (id) 2001-02-08
ZA200004016B (en) 2001-07-25
JP4558198B2 (ja) 2010-10-06
CN1293577A (zh) 2001-05-02
HUP0101189A2 (hu) 2001-08-28
SK284499B6 (sk) 2005-05-05
PT1066056E (pt) 2002-12-31
DK42099A (da) 1999-08-16
DE69902154T2 (de) 2003-03-06
NZ505983A (en) 2002-11-26
WO1999048533A1 (en) 1999-09-30
KR20010034641A (ko) 2001-04-25
CZ300823B6 (cs) 2009-08-19
JP2002507582A (ja) 2002-03-12
HUP0101189A3 (en) 2003-12-29
TR200002733T2 (tr) 2000-12-21
AU740432B2 (en) 2001-11-01
DE69902154T3 (de) 2009-07-09
EP1066056B1 (en) 2002-07-17
CZ20003535A3 (cs) 2001-04-11
PL195582B1 (pl) 2007-10-31
HU228483B1 (en) 2013-03-28
BRPI9908914B8 (pt) 2021-07-06

Similar Documents

Publication Publication Date Title
ES2180279T3 (es) Compuesto de hierro-dextrano para utilizacion como componente en composicion terapeutica para profilaxis o tratamiento de deficiencia de hierro, procedimiento para su produccion y utilizacion del mismo para preparacion de composicion terapeutica administrable por via parenteral.
AR008378A1 (es) Conjudados de interferon
DK1455605T3 (da) Læskedrikerstatning
BR0210056A (pt) composições e métodos para tratamento de hiperplasia
NZ701559A (en) Compositions comprising povidone-iodine
ES2131266T3 (es) Copolimeros de bloques lineales, procedimiento para su preparacion y composiciones adhesivas que los contienen.
BRPI9908182C1 (pt) composições de proteína de matriz para cura de feridas
HRP20030046B1 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
ES2130268T3 (es) Preparados de acido hialuronico de bajo peso molecular, para estimulacion de formacion de huesos.
RU2010117173A (ru) Глазные композиции на основе полисахарида семян тамаринда и гиалуроновой кислоты
BR0111506A (pt) Complexos de droga macromoleculares e composições contendo os mesmos
BRPI0718078B8 (pt) implante de ancoragem e fixação e conjunto cirúrgico para sua implantação
AR038203A1 (es) Cuerpos de inclusion de fosfolipidos y uso de los mismos en tratamientos medicos
EP2060255A3 (en) Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection
ES2140240T3 (es) Elastomeros microcelulares con propiedades y capacidad de tratamiento mejorados.
CO5190674A1 (es) Tratamiento de desordenes neuroticos desordenes neuroticos
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
HK1110768A1 (en) 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
CA2150234C (en) COMBINATION OF ATOVAQUONE AND PROGUANIL FOR THE TREATMENT OF PROTOZOA INFECTION
MX2023006261A (es) Composiciones que comprenden oligosacaridos de la leche humana para uso en un sujeto para apoyar la duracion del sue?o nocturno.
BR0214487A (pt) Composição farmacêutica que compreende uma combinação de metformina e um ácido 4-oxobutanóico, e o uso da mesma para o tratamento de diabetes
WO2021097434A8 (en) Fibroblast therapy for inflammatory bowel disease
BR9916858A (pt) ((aminoiminometil)amino)alcanocarboxamidas e asaplicações das mesmas em terapia
EP0948338B1 (en) Utilization of an egg-based preparation as an antidepressant